PITTSBURGH — Mylan N.V. has completed its $9.9 billion deal to acquire Sweden-based Meda AB. Mylan had received Federal Trade Commission clearance for the transaction in late July. The deal was announced in February. The combination of Mylan and Meda creates a leading pharmaceutical company with a strong portfolio of brand-name and generic drugs and
PITTSBURGH — Mylan N.V. this week introduced two new generic drugs in the U.S. market. On Monday, the company announced final Food and Drug Administration approval for dextroamphetamine sulfate extended-release capsules — in dosages of 5 mg, 10 mg and 15 mg — and finasteride tablets 1 mg. Mylan’s dextroamphetamine sulfate ER capsules are a
NEW YORK — The Federal Trade Commission has given its approval to two major pharma acquisitions: Teva Pharmaceutical Industries Ltd.’s $40 billion deal to buy Allergan plc’s generics business and Mylan N.V.’s $9.9 billion deal to acquire Meda AB. Teva said that with the FTC’s acceptance of the proposed consent order, the company has satisfied
PITTSBURGH — Mylan N.V. has launched fenofibrate tablets 40 mg and 120 mg, a cholesterol-lowering drug, in the United States. Mylan said Wednesday that its fenofibrate product is a generic version of Fenoglide tablets from Santarus. Fenofibrate tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides and
COLORADO SPRINGS, Colo. — Henry Dale Smith Jr., chairman and chief executive officer of H.D. Smith Holding Co., has received the 2016 Nexus Award for Lifetime Achievement from the HDA Research Foundation. Smith was presented the award, the pharmaceutical distribution industry’s highest individual honor, at the Healthcare Distribution Alliance (HDA) 2016 Business and Leadership Conference
PITTSBURGH — Mylan N.V. has launched clindamycin palmitate hydrochloride oral solution 75 mg/5 ml, an antibiotic, in the United States. Mylan said Friday that its product is a generic version of Cleocin solution by Pharmacia/Upjohn (Pfizer) . Mylan received final approval from the Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for
PITTSBURGH — Mylan N.V. has launched doxycycline hyclate delayed-release tablets (200 mg), an antibiotic, in the United States. Mylan said its doxycycline product is a generic version of Doryx 200-mg delayed-release tablets from Mayne Pharma. A tetracycline-class antimicrobial, doxycycline hyclate DR tablets are a indicated as adjunctive therapy for severe acne. U.S. sales of 200-mg doxycycline
PITTSBURGH — Mylan N.V. has entered an agreement to buy the nonsterile, topicals-focused specialty and generics business of Renaissance Acquisition Holdings LLC for $950 million in cash. Mylan said Friday that the Renaissance business, which has about 1,200 employees and posted sales of $370 million in 2015, will bring 25 branded and generic topical products,
PITTSBURGH — Mylan N.V. has launched metoprolol tartrate tablets, a hypertension drug, in dosages of 37.5 mg and 75 mg in the United States. Mylan said its products, a generic version of Lopressor tablets from Novartis, are the first and only available intermediate dosage strengths between the current metoprolol tartrate tablets, which come in strengths
PITTSBURGH — Mylan N.V. has rolled out tramadol hydrochloride extended-release tablets, a chronic pain medication, in the United States. The drug maker said its product comes in dosages of 100 mg, 200 mg and 300 mg and is a generic version of Ultram ER tablets from Valeant Pharmaceuticals International. Tramadol hydrochloride ER tablets are indicated
ORLANDO, Fla. — The Generic Pharmaceutical Association (GPhA) has elected Heather Bresch, chief executive officer of Mylan, to chair its board of directors this year. GPhA, which announced the move at its 2016 Annual Meeting here, also named other officers to its 2016 board and executive committee: Jeff Watson, president of global generics at Apotex,
HERTFORDSHIRE, England — Mylan N.V. plans to acquire Sweden-based pharmaceuticals manufacturer Meda AB in a deal valued at $9.9 billion, including debt. Mylan said late Wednesday that the offer to Meda includes cash and Mylan shares, with the equity portion valued at $7.2 billion. Executives from both companies noted that a Mylan-Meda combination would create
NEW YORK — Mylan N.V. and Teva Pharmaceutical Industries Ltd. have rolled out norgestimate/ethinyl estradiol tablets, a birth control pill, in the United States. The companies said Tuesday that their products are generic versions of Janssen Pharmaceuticals Inc.’s Ortho Tri-Cyclen Lo tablets. Mylan said its norgestimate/ethinyl estradiol tablets — available in dosages of 0.18 mg/0.025
NEW YORK — Shareholders of Perrigo Co. plc have rejected a hostile bid by Mylan N.V. to acquire the company in a deal valued at about $27 billion. Perrigo said Friday that shareholders holding more than 60% of its outstanding shares declined to tender into Mylan’s offer by the 8 a.m. ET deadline. The offer
